Therapy of Bronchiectasis

被引:2
|
作者
Rademacher, J. [1 ]
Schweigert, M. [2 ]
机构
[1] Hannover Med Sch, Klin Pneumol, Carl Neuberg Str 1, D-30625 Hannover, Germany
[2] Stadt Klinikum Dresden Friedrichstadt, Klin Allgemein Viszeral & Thoraxchirurg, Dresden, Germany
来源
ZENTRALBLATT FUR CHIRURGIE | 2015年 / 140卷 / 01期
关键词
bronchia; bronchiectasis; NCFB; lung disease; CYSTIC FIBROSIS BRONCHIECTASIS; RANDOMIZED CONTROLLED-TRIAL; NON-CF BRONCHIECTASIS; PLACEBO-CONTROLLED TRIAL; SURGICAL-MANAGEMENT; LUNG TRANSPLANTATION; DOUBLE-BLIND; PSEUDOMONAS-AERUGINOSA; DRY POWDER; LONG-TERM;
D O I
10.1055/s-0033-1358087
中图分类号
R61 [外科手术学];
学科分类号
摘要
The prevalence of bronchiectasis not due to cystic fibrosis (NCFB) increases with older age. Because of multifaceted etiology of bronchiectasis an extensive diagnostic approach is essential. This includes in-depth anamnesis and a high resolution CT scan of the chest (HRCT). The pathophysiological mechanism with infection, inflammation, secretion retention and destruction determine the therapeutic options. In patients with high rates of exacerbations and severe diseases physicians should think of inhaled antibiotics and macrolids. In case of localized bronchiectasis and failure of conventional therapy surgery of bronchiectasis is an effective treatment option. In some cases surgery is necessary due to haemoptysis, aspergilloma, lung abscess and pleuraempyema. To improve the treatment options of bronchiectasis results of epidemiological, basically and clinical research trials are expected and needed.
引用
收藏
页码:113 / 126
页数:14
相关论文
共 50 条
  • [32] Acute exacerbation of bronchiectasis and the impact on the duration of antibiotic therapy
    Oscanoa Huaman, Patricia Elena
    Amaro Rodriguez, Rosanel
    Gabarrus Barri, Albert
    Serrano, Victoria Alcaraz
    Scioscia, Giulia
    Menendez, Rosario
    Mendez, Raul
    Torres Marti, Antoni
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [33] NEBULIZATION THERAPY IN BRONCHIECTASIS - THE USE OF PENICILLIN AND STREPTOMYCIN AEROSOLS
    OLSEN, AM
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1947, 134 (11): : 947 - 953
  • [34] Evaluating Success of Therapy for Bronchiectasis What End Points to Use?
    Smith, Maeve P.
    Hill, Adam T.
    CLINICS IN CHEST MEDICINE, 2012, 33 (02) : 329 - +
  • [35] Registry Outcomes For Hfcwo Vest Therapy In Adult Patients With Bronchiectasis
    Hansen, G.
    Daignault, S.
    Stiglich, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [36] Inhaled medication therapy for bronchiectasis: status quo and the next frontier
    Chen, Chun-lan
    Huang, Yan
    Gao, Yong-hua
    Chen, Rong-chang
    Zhong, Nan-shan
    Guan, Wei-jie
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (03) : 211 - 218
  • [37] Immune dysfunction in bronchiectasis: blocking antibodies and a role for IVIG therapy?
    Thirugnanasothy, L.
    Davison, J.
    Whitters, D.
    Stockley, R. A.
    MacLennan, C. A.
    Cunningham, A. F.
    Kanagasundaram, S.
    Spickett, G.
    Stroud, C.
    Wells, T. J.
    Henderson, I. R.
    De Soyza, A.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2015, 45 (02): : 502 - 502
  • [38] Non-CF-Bronchiectasis-: Genesis, Etiology, Antibiotic therapy
    Welte, T.
    INFECTION, 2012, 40 : 66 - 68
  • [39] Prognostic Factor of Airflow Obstruction and bronchodilator therapy in Patients with Bronchiectasis
    Lee, Young Min
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [40] Exhaled nitric oxide in bronchiectasis: the effects of inhaled corticosteroid therapy
    Tsang, KW
    Tan, KC
    Ho, PL
    Ooi, GC
    Khong, PL
    Leung, R
    Mak, JC
    Tipoe, GL
    Ko, C
    Lam, WK
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2004, 8 (11) : 1301 - 1307